Bicyclic compounds and their uses as dual c-SRC/JAK inhibitors
The present invention relates to substituted aromatic bicyclic compounds containing pyrimidine and pyridine rings of formula (I) having the structure as well as pharmaceutically acceptable salts thereof. The compounds of the present invention are useful as tyrosine kinase inhibitors, preferably SRC family kinases (SFKs) inhibitors, in particular as multi SFK/JAK. kinases inhibitors and even preferably as dual c-SRC/JAK kinases inhibitors, thereby inhibiting the STAT3 activation and therefore abnormal growth of particular cell types. Notably, the compounds of the present invention are useful for the treatment or inhibition of certain diseases that are the result of deregulation of STAT3.
1. A method for the activation of STAT3 pathway, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) having the structure
wherein
R1 is H, aryl, substituted aryl, alkyl, substituted alkyl, heteroaryl, substituted heteroaryl, heterocyclyl, substituted heterocyclyl, heterocyclylalkyl or substituted heterocyclylalkyl;
X is CH 2 or C═O;
R2 is H, (C 1 -C 6 )alkyl, halogen, CF 3 , or —O—(C 1 -C 6 )alkyl;
Y is —NHCO—, —CONH—, —NHSO 2 —, —NH—, —NCH 3 —CO—, —NHCH 2 —, O, —NHCONH— or —NHCOCH 2 —;
R3 is alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl or
or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is an inhibitor of c-SRC and JAK2.
2. The method of claim 1 , wherein the subject in need thereof is suffering from cancer, an auto-immune disease, a bone related disease or a haematological disease.
3. The method of claim 2 , wherein said cancer is breast cancer, head and neck cancer, melanoma, ovarian cancer, lung cancer, pancreatic cancer, colon cancer, uterine cancer, gastric cancer, renal cancer, bladder cancer, liver cancer or prostate cancer.
4. The method of claim 2 , wherein said cancer is multiple myeloma, a leukaemia, a myeloproliferative neoplasm or a lymphoma.
5. The method of claim 1 , wherein said administration is oral, transdermal or parenteral.
6. The method of claim 1 , wherein the compound of formula (I) corresponds in structure to formula (II):
wherein
R1 is hydrogen; (C 1 -C 4 )alkyl; phenyl; substituted phenyl; pyridine; or substituted pyridine;
X is CH 2 or C═O;
R2 is H; (C 1 -C 6 )alkyl; halogen; or —O—(C 1 -C 6 )alkyl;
R3 is selected from the group consisting of (C 1 -C 6 )alkyl; cycloalkyl; substituted cycloalkyl; heterocycloalkyl; aryl; substituted aryl; heteroaryl; substituted heteroaryl;
and wherein the substituents are independently selected from the group consisting of C 1 -C 4 linear or branched alkyl; halo or nitrile substituted C 1 -C 4 -alkyl; —O—(C 1 -C 4 )alkyl; and halogen;
or a pharmaceutically acceptable salt thereof.
7. The method of claim 1 , wherein R3 is selected from the group consisting of:
8. The method of claim 1 , wherein
R1 is substituted phenyl or substituted pyridine;
X is CH 2 or C═O;
R2 is H, CH 3 , Cl or F;
R3 is selected from the group consisting of:
and substituted phenyl, wherein the substituents are independently selected from the group consisting of Cl, F, Br, CF 3 and CH 3 .
9. The method of claim 1 , wherein R1 is selected from the group consisting of:
and
R3 is selected from the group consisting of:
10. The method of claim 1 , wherein the compound of formula (I) is selected from the group consisting of:
N-(4-Methyl-3-{2-[4-(4-methyl-piperazine-1-carbonyl)-phenylamino]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-3-trifluoromethyl-benzamide;
N-(4-Methyl-3-{2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-3-trifluoromethyl-benzamide;
5-{6-[2-Methyl-5-(3-trifluoromethyl-benzoylamino)-phenyl]-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-2-ylamino}-pyridine-2-carboxylic acid cyclopropylamide;
N-{3-[2-(4-Cyclopropylsulfamoyl-phenylamino)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]-4-methyl-phenyl}-3-trifluoromethyl-benzamide;
N-(4-Chloro-3-{2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-3-trifluoromethyl-benzamide;
4-Trifluoromethyl-pyridine-2-carboxylic acid {4-chloro-3-[2-(4-methylcarbamoyl-phenylamino)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]-phenyl}-amide;
4,4,4-Trifluoro-3-methyl-N-[4-methyl-3-(2-{4-[2-(4-methyl-piperazin-1-yl)-ethoxy]-phenylamino}-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)-phenyl]-butyramide;
1-Cyclopentyl-3-(4-methyl-3-{2-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylamino]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-urea;
N-(4-Methyl-3-{5-oxo-2-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylamino]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-3-trifluoromethyl-benzamide;
N-{4-Chloro-3-[2-(4-cyclopropylcarbamoylmethoxy-phenylamino)-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]-phenyl}-3-trifluoromethyl-benzamide;
N-(4-Chloro-3-{2-[3-methyl-4-(4-methyl-piperazin-1-yl)-phenylamino]-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-3-trifluoromethyl-benzamide;
3-Bromo-N-(4-methyl-3-{2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-benzamide; and
N-(4-Chloro-3-{2-[4-(4-methyl-piperazin-1-ylmethyl)-phenylamino]-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-3-trifluoromethyl-benzamide;
or a pharmaceutically acceptable salt thereof.
11. The method of claim 1 , wherein the compound of formula (I) is selected from the group consisting of:
N-(4-Methyl-3-{2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-3-trifluoromethyl-benzamide;
5-{6-[2-Methyl-5-(3-trifluoromethyl-benzoylamino)-phenyl]-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-2-ylamino}-pyridine-2-carboxylic acid cyclopropylamide; and
4-Trifluoromethyl-pyridine-2-carboxylic acid {4-chloro-3-[2-(4-methylcarbamoyl-phenylamino)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]-phenyl}-amide;
or a pharmaceutically acceptable salt thereof.
12. The method of claim 1 , wherein the compound of formula (I) is selected from the group consisting of:
N-(4-Chloro-3-{2-[3-methyl-4-(4-methyl-piperazin-1-yl)-phenylamino]-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-3-trifluoromethyl-benzamide; and
N-{4-Chloro-3-[2-(4-cyclopropylcarbamoylmethoxy-phenylamino)-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]-phenyl}-3-trifluoromethyl-benzamide.
13. The method of claim 3 , wherein the compound is selected from the group consisting of:
N-(4-Methyl-3-{2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-3-trifluoromethyl-benzamide;
5-{6-[2-Methyl-5-(3-trifluoromethyl-benzoylamino)-phenyl]-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-2-ylamino}-pyridine-2-carboxylic acid cyclopropylamide; and
4-Trifluoromethyl-pyridine-2-carboxylic acid {4-chloro-3-[2-(4-methylcarbamoyl-phenylamino)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]-phenyl}-amide;
or a pharmaceutically acceptable salt thereof.
14. The method of claim 4 , wherein the compound is selected from the group consisting of:
N-(4-Chloro-3-{2-[3-methyl-4-(4-methyl-piperazin-1-yl)-phenylamino]-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-3-trifluoromethyl-benzamide; and
N-{4-Chloro-3-[2-(4-cyclopropylcarbamoylmethoxy-phenylamino)-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]-phenyl}-3-trifluoromethyl-benzamide;
or a pharmaceutically acceptable salt thereof.